CCA
TXMD icon

Cygnus Capital Advisors’s TherapeuticsMD TXMD Stock Holding History

Cygnus Capital Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18 Buy
+9,069
New +$20.4K 0.01% 89

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cygnus Capital Advisors's TXMD Position: Q1 2026 in Review

Cygnus Capital Advisors opened a new position in TherapeuticsMD (TXMD) in Q1 2026: 9,069 shares worth $18. The stake represents 0.01% of the portfolio and ranks #89 among its holdings.

49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Cygnus Capital Advisors held 9,069 shares of TherapeuticsMD worth $18 as of Q1 2026.
  • TherapeuticsMD was a new Cygnus Capital Advisors position in Q1 2026.
  • TherapeuticsMD made up 0.01% of Cygnus Capital Advisors's portfolio in Q1 2026, its #89 holding.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.